A Multicenter Phase II Study of Docetaxel 60 mg/m2 as First-Line Chemotherapy in Patients with Advanced or Recurrent Breast Cancer

Ishikawa, Takashi; Shimizu, Satoru; Inaba, Masaaki; Asaga, Taro; Katayama, Kiyofumi; Fukuda, Mamoru; Tokuda, Yutaka; Ishida, Kazuo; Fukuma, Eisuke; Suda, Takashi; Hamaguchi, Yohei; Ishiyama, Akira; Shimada, Hiroshi

doi:10.1007/bf02968045

Cited by 7 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recent introduction of novel biological agents might increase survival compared to agents introduced decades ago; however, sufficient follow-up has not yet been completed. Response rates for first-line chemotherapies (alone or incombination) in MBC are approximately 30-70%; however, time to disease progression following treatment with these agents is only 7-10 months [10][11][12]. Following disease progression with first-line therapies for MBC, the response rate for additional single-agent or combination therapies falls to approximately 20-30%, and the median duration of response is less than 6 months [13].…”

Section: Metastatic Breast Cancer and The Impact Of Resistancementioning

confidence: 99%

Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer

Perez

2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

Despite advances in treatment of patients with metastatic breast cancer (MBC), prognosis remains poor and median survival is 2-3 years. Resistance to antineoplastics mediated by many factors, potentially including overexpression of drug efflux proteins or altered beta-tubulin isotype expression limits the effectiveness of MBC chemotherapy. Capecitabine, approved for anthracycline- and taxane-resistant MBC, has produced modest responses, highlighting the need for more effective treatments for MBC resistant to multiple chemotherapeutic agents. Agents with potential to reverse drug resistance have not proven effective. Albumin-bound paclitaxel is a formulation that may enhance delivery to tumor tissues. Conversely, ixabepilone, an epothilone analog, has been reported to have lower susceptibility to at least some mechanisms of tumor resistance and clinical activity in resistant/refractory MBC. The topoisomerase-I inhibitor irinotecan also has low cross-resistance with other antineoplastics, and has shown some activity against refractory MBC. Development of new agents and identification of genetic biomarkers in translational studies promise to improve management of patients with resistant/refractory breast cancer.

show abstract

Section: Metastatic Breast Cancer and The Impact Of Resistancementioning

confidence: 99%

Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer

Perez

2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Acquired resistance, the development of resistance over the course of treatment, can come about through a variety of mechanisms and occurs in most tumors that initially respond to therapy [4]. Patients who present with metastatic breast cancer respond to first-line chemotherapies, which include anthracyclines and taxanes, at a rate of 30–70% [8–11]. The time to disease progression for these patients is approximately 6–10 months [8–11].…”

Section: Introductionmentioning

confidence: 99%

“…Patients who present with metastatic breast cancer respond to first-line chemotherapies, which include anthracyclines and taxanes, at a rate of 30–70% [8–11]. The time to disease progression for these patients is approximately 6–10 months [8–11]. …”

Section: Introductionmentioning

confidence: 99%

The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment

Haagenson

2010

Cancer Metastasis Rev

View full text Add to dashboard Cite

Chemotherapy resistance is an important problem often encountered during the course of breast cancer treatment. In order to design rational and efficacious therapies, the molecular mechanisms used by cells to develop resistance must be investigated. One mechanism employed by cancer cells is to alter cell signaling. This review examines the role of mitogen-activated protein kinases (MAPKs) and their endogenous negative regulators, mitogen-activated protein kinase phosphatases (MKPs), in chemotherapy resistance in breast cancer. MAPK signaling is activated in response to both growth factors and cellular stress. MKPs dephosphorylate MAPKs and are part of the dual-specificity family of phosphatases. MAPKs have been shown to be involved in resistance to tamoxifen, and MKPs have been linked to resistance to treatment with doxorubicin, mechlorethamine, paclitaxel, proteasome inhibitors, and oxidative-stress-induced cell death in breast cancer. The role of MKPs in tamoxifen resistance and the elucidation of the mechanisms involved with resistance to standard chemotherapy agents need to be investigated further. Growing evidence suggests that modulating MKP-1 activity could be a viable option to make breast cancer chemotherapy more effective.

show abstract

Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials

et al. 2011

View full text Add to dashboard Cite

show abstract

A Multicenter Phase II Study of Docetaxel 60 mg/m2 as First-Line Chemotherapy in Patients with Advanced or Recurrent Breast Cancer

Abstract: Docetaxel achieved good disease control with mild adverse events in first-line treatment at a dosage of 60 mg/m2.

Cited by 7 publications

References 15 publications

Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer

Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer

The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment

Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials

Contact Info

Product

Resources

About